Finance

Lists
Why is JAZZ down 2,93%?
Dive Deeper
JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
210,39 US$
-2,93%
(-6,36) 1D
210,39 US$
0,00% (0,00)
After hours
Closed: 13 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for JAZZ...
Open
216,86 US$
High
216,86 US$
Low
209,34 US$
Mkt. cap
13,66 მლრდ.
Avg. vol.
805,39 ათ.
Volume
812,58 ათ.
P/E ratio
14,39
52-wk high
266,38 US$
52-wk low
128,80 US$
EPS
14,63 US$
Beta
0,37
Shares outstanding
64,92 მლნ.
No. of employees
3 ათ.
Open
216,86 US$
High
216,86 US$
Low
209,34 US$
Mkt. cap
13,66 მლრდ.
Avg. vol.
805,39 ათ.
Volume
812,58 ათ.
P/E ratio
14,39
52-wk high
266,38 US$
52-wk low
128,80 US$
EPS
14,63 US$
Beta
0,37
Shares outstanding
64,92 მლნ.
No. of employees
3 ათ.
News stories
From web sources and news partners
Profile
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
About Jazz Pharmaceuticals PLC
CEOბრუს სი კოზად
Employees2,89 ათ.
Founded2003
Headquarters-
SectorPharmaceutical industry
Analyst ratings
Based on 18 analysts giving stock ratings to JAZZ in the past 3 months
Strong buy
Buy
17
Hold
1
Sell
0
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for JAZZ in the last 3 months.
Highest
Current 210,39 US$
337,00 US$ (+60,18%)
Average
298,17 US$ (+41,72%)
Lowest
229,00 US$ (+8,85%)
Analyst
Recommendation
Action
Price target
Projected
Date
Etzer Darout
Barclays
Buy
Maintained
271,00 US$
+28,8%
10/13/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
313,00 US$
+48,8%
10/09/2026
Leonid Timashev
RBC Capital
Buy
Maintained
296,00 US$
+40,7%
10/08/2026
Gregory Renza
Truist Financial
Buy
Maintained
286,00 US$
+35,9%
10/07/2026
Geoff Meacham
Citi
Buy
Initiated
325,00 US$
+54,5%
10/01/2026
David Amsellem
Piper Sandler
Buy
Reiterated
310,00 US$
+47,3%
09/28/2026
Jeffrey Walch
Bernstein
Hold
Maintained
229,00 US$
+8,8%
09/25/2026
Andrea Newkirk
Goldman Sachs
Buy
Initiated
337,00 US$
+60,2%
09/24/2026
Ashwani Verma
UBS
Buy
Reiterated
337,00 US$
+60,2%
09/14/2026
Gary Nachman
Canaccord Genuity
Buy
Maintained
300,00 US$
+42,6%
08/31/2026
Joseph Thome
TD Cowen
Buy
Maintained
300,00 US$
+42,6%
08/31/2026
Ami Fadia
Needham
Buy
Reiterated
310,00 US$
+47,3%
08/31/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
322,00 US$
+53%
08/26/2026
David Hoang
Deutsche Bank
Buy
Maintained
300,00 US$
+42,6%
08/26/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
300,00 US$
+42,6%
08/10/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
275,00 US$
+30,7%
08/04/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
276,00 US$
+31,2%
08/04/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
280,00 US$
+33,1%
08/04/2026
Unknown Analyst
Jefferies
Buy
Maintained
282,00 US$
+34%
07/13/2026
Joon Lee
Truist Financial
Buy
Initiated
256,00 US$
+21,7%
06/09/2026
Unknown Analyst
Bernstein
Hold
Maintained
-
-
06/01/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
265,00 US$
+26%
05/20/2026
Tiago Fauth
Raymond James
Buy
Maintained
239,00 US$
+13,6%
05/06/2026
Unknown Analyst
Raymond James
Buy
Maintained
239,00 US$
+13,6%
05/06/2026
Last report
3 აგვ. 2026
Fiscal period
Q2 2026
5,71 US$ / 6,18 US$
-7,54%miss
Revenue / Est. (USD)
1,21 მლრდ. / 1,11 მლრდ.
+8,43%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,13 მლრდ.
1,20 მლრდ.
1,07 მლრდ.
1,21 მლრდ.
Cost of goods sold
128,88 მლნ.
112,92 მლნ.
96,60 მლნ.
116,40 მლნ.
Cost of revenue
128,88 მლნ.
112,92 მლნ.
96,60 მლნ.
116,40 მლნ.
Research and development expenses
198,20 მლნ.
172,66 მლნ.
196,00 მლნ.
207,50 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
379,15 მლნ.
418,46 მლნ.
352,70 მლნ.
389,20 მლნ.
Operating expense
745,72 მლნ.
760,86 მლნ.
721,00 მლნ.
766,70 მლნ.
Total operating expenses
874,60 მლნ.
873,79 მლნ.
817,60 მლნ.
883,10 მლნ.
Operating income
251,51 მლნ.
324,14 მლნ.
251,30 მლნ.
325,20 მლნ.
Other non operating income
-
-
122,80 მლნ.
-
EBT including unusual items
8,99 მლნ.
208,41 მლნ.
299,20 მლნ.
210,90 მლნ.
EBT excluding unusual items
202,99 მლნ.
278,02 მლნ.
336,70 მლნ.
287,90 მლნ.
Income tax expense
-242,42 მლნ.
4,96 მლნ.
6,10 მლნ.
18,10 მლნ.
Effective tax rate
-2 697,20%
2,38%
2,04%
8,58%
Other operating expenses
-
-
-
-
Net income
251,41 მლნ.
203,45 მლნ.
293,10 მლნ.
192,80 მლნ.
Net profit margin
22,33%
16,98%
27,42%
15,96%
Earnings per share
8,13
6,64
6,34
5,71
Interest and investment income
18,60 მლნ.
20,50 მლნ.
23,40 მლნ.
25,30 მლნ.
Interest expense
-67,18 მლნ.
-65,91 მლნ.
-63,30 მლნ.
-62,40 მლნ.
Net interest expenses
-48,58 მლნ.
-45,41 მლნ.
-39,90 მლნ.
-37,10 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
429,76 მლნ.
503,31 მლნ.
432,70 მლნ.
504,30 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები